Editor Profile

Helmut Albrecht, MD

Contributing Editor

About the NEJM Journal Watch Infectious Diseases Board

Helmut Albrecht, MD, is the Heyward Gibbes Distinguished Professor of Medicine and Chief of the Division of Infectious Diseases at the University of South Carolina School of Medicine. He has served as an investigator of multiple national and international trials, and has published several book chapters and more than 100 articles in peer-reviewed journals. He is a founding member and former president of KAAD (Klinische Arbeitsgemeinschaft AIDS Deutschland/German AIDS Clinical Trial Group). Dr. Albrecht served on the NEJM Journal Watch AIDS Clinical Care Editorial Board since 2004. He has been a member of the NEJM Journal Watch Infectious Diseases Editorial Board since May 2014.


Grant / Research support

Health Resources and Services Administration

Summaries by Helmut Albrecht

  • February 20, 2015

    Treating HIV/HCV-Coinfected PatientsFree

    1. Helmut Albrecht, MD

    A sofosbuvir/ribavirin combination cured infections with hepatitis C virus genotypes 1 through 4 in 84% to 89% of HIV-coinfected patients.

  • October 7, 2014

    Comparison of the “Other” Regimens for HIV-Naive PatientsFree

    1. Helmut Albrecht, MD

    Darunavir was superior to atazanavir — and raltegravir was superior to both — for the combined efficacy/tolerability endpoint, but between-regimen differences were entirely driven by tolerability.

  • March 7, 2014

    Low-Dose Efavirenz — The New Standard?

    1. Helmut Albrecht, MD

    Efavirenz at 400 mg daily was as effective as — and better tolerated than — the standard 600-mg dose and would provide substantial savings.

  • January 21, 2014

    Severe Chronic Kidney Disease in HIV-Infected Patients

    1. Helmut Albrecht, MD

    Current CD4-cell count and traditional non-HIV risk factors — but not the antiretrovirals used — were the strongest predictors.

  • January 10, 2014

    Telaprevir in Acute HCV Infection

    1. Helmut Albrecht, MD

    A small pilot study showed promising efficacy and an acceptable safety profile when telaprevir was added to a standard interferon/ribavirin regimen in HIV patients with acute HCV infection.

  • October 15, 2013

    Elite HIV Controllers

    1. Helmut Albrecht, MD

    In a large group of seroconverters, 1.4% were elite controllers, and most of these individuals maintained control for longer than 20 years.